Clinical Trials and Efficacy - The BIM-IOL System achieved a mean intraocular pressure (IOP) reduction of 37% at 36 months in the first-in-human trial, with 95% of evaluable patients off all topical IOP-lowering drops[22]. - In the Phase 1/2 trial, patients in the 78 mcg and 39 mcg dose groups achieved mean IOP reductions of 37% and 36% respectively at three months, with 97% off topical drops at both three and twelve months[22]. - The company plans to initiate two registrational Phase 3 clinical trials for the BIM-IOL System, enrolling approximately 400 patients each, with expected completion of enrollment in 2027 and a 505(b)(2) NDA submission planned for 2028[35]. - The Phase 1/2 trial of the BIM-IOL System demonstrated a mean IOP reduction of 37% and 36% in the 78 mcg and 39 mcg dose groups, respectively, at three months[113]. - At three months, 98% of patients in the 78 mcg group and 96% in the 39 mcg group were off all topical IOP-lowering medications[116]. - The primary objective of the Phase 3 program is to evaluate the safety and IOP-lowering efficacy of the BIM-IOL System compared to a standard of care commercial IOL[135]. - The Phase 3 clinical trials for the BIM-IOL System were initiated in July 2025, with an expected enrollment of approximately 400 patients across 45 clinical sites[130]. - 100% of evaluable patients achieved an IOP reduction of more than 20% from baseline, and 90.5% maintained an IOP ≤18 mmHg through 36 months[99]. - The BIM-IOL System was well-tolerated, with all adverse events related to the cataract procedure and none deemed associated with the product candidate[104]. Market Opportunity and Strategy - The total addressable market for the BIM-IOL System in the U.S. is estimated at approximately $13 billion, targeting one million glaucoma and ocular hypertension patients expected to undergo cataract surgery in 2025[26]. - The U.S. is expected to see approximately five million cataract surgeries in 2025, growing at a rate of 3% to 4% annually[57]. - The total addressable market for OAG/OHT and cataract patients is estimated to be around $13 billion[58]. - Approximately 90% of cataract surgeries in the U.S. are performed in Ambulatory Surgery Centers (ASCs), which presents an opportunity for incremental revenue[57]. - The company estimates that the top 5% of cataract surgeons perform over 25% of procedures, allowing for an efficient sales force to capture market opportunities[145]. - The global glaucoma market is expected to grow significantly due to an aging population and increased access to ophthalmic care[60]. - By 2025, over 80 million people worldwide are projected to be affected by OAG, with 48 million impacted by OHT[59][68]. - The market opportunity focuses on the glaucoma market, addressing the need for patient-centric innovations in the treatment of OAG and OHT[56]. Product Development and Innovation - The BIM-IOL System is designed to integrate into existing cataract surgery workflows, potentially tripling the number of cataract surgeons treating open-angle glaucoma (OAG) or ocular hypertension (OHT) during routine procedures[24]. - The SpyGlass Platform aims to provide consistent and predictable drug delivery over three years, reducing the need for daily topical medications[24]. - The company is also developing a non-IOL-based, ring-shaped sustained-release implant (BIM-DRS) for extended care of patients with OAG or OHT, with plans to advance into first-in-human trials in 2026[31]. - The BIM-IOL System is designed to reduce daily exposure to bimatoprost, potentially lowering the risk of adverse events, with no product-related adverse events observed at 36 months in clinical trials[52]. - The Drug Pad-IOL System is designed to integrate seamlessly into routine cataract surgery, enhancing procedural workflow and patient outcomes[43]. - The BIM-IOL System is designed to provide sustained delivery of bimatoprost over three years, potentially reducing the need for daily topical medications and aiming to triple the number of cataract surgeons treating OAG or OHT during cataract surgery[86]. - The BIM-DRS is being developed as a removable and replaceable implant for continuous care, with plans to advance into first-in-human trials in 2026[35]. - The SpyGlass Platform is designed to integrate approved medicines into sustained-release systems, initially focusing on the Drug Pad-IOL System and non-IOL-based DRS for treating elevated IOP in patients with OAG or OHT[35]. Financial and Investment Overview - Approximately $200 million has been raised in financing since the company's inception, supported by a syndicate of investors including New Enterprise Associates and RA Capital Management[40]. - The company retains exclusive worldwide development and commercialization rights to its pipeline programs, which include various drug delivery systems targeting chronic eye conditions[27]. - The company has established a robust intellectual property portfolio with patents expected to expire between 2039 and 2043, and plans to strengthen this portfolio through new filings[44]. Regulatory and Compliance - The company plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA in 2028, following the completion of Phase 3 trials expected in 2027[22]. - The NDA submission process includes a preliminary review by the FDA within 60 days, with a goal to review applications within ten months, or six months for priority review[184]. - The FDA requires extensive compliance for drug and device products, including preclinical testing, clinical trials, and manufacturing standards[175][176]. - The company must conduct pediatric clinical trials for most drugs under the Pediatric Research Equity Act (PREA) unless a deferral or waiver is granted[188]. - The FDA mandates ongoing compliance with regulatory standards post-approval, including record-keeping and reporting of adverse experiences[197]. - The company must maintain a device master file, device history file, and complaint files as part of compliance with quality regulations[219]. Intellectual Property and Competition - The patent portfolio includes 15 issued U.S. patents and 31 pending applications, with expiration dates projected between 2039 and 2043[158]. - The company faces competition from established pharmaceutical and medical technology firms, which may have greater resources and expertise in R&D and marketing[153]. - The company relies on trade secret protection and know-how to maintain its proprietary position in chemistries and manufacturing technologies[165]. - The company has secured IP protection in key global markets, including Western Europe, Japan, Australia, and Canada, to facilitate international expansion[58].

IPO and Fundraising - The company completed its Initial Public Offering (IPO) on May 13, 2024, raising gross proceeds of $287.5 million from the sale of 28,750,000 units at a price of $10.00 per unit[19]. - The company also sold 7,000,000 private placement warrants for $1.00 each, generating an additional $7 million in gross proceeds[20]. - Offering costs incurred in connection with the IPO were approximately $20.27 million, including deferred underwriting commissions of about $13.69 million[22]. - The company plans to utilize net proceeds from the IPO primarily for completing an initial business combination, which must have a fair market value of at least 80% of the net assets held in the Trust Account[23]. - The company has approximately $900,000 available outside the Trust Account to fund working capital requirements, which may not be sufficient for operations over the next 24 months[83]. Business Combination Strategy - The company intends to target businesses with an enterprise valuation between $1.0 billion and $5.0 billion for its initial business combination[26]. - The management team aims to identify companies with strong growth potential and sustainable competitive advantages[28]. - The company intends to seek targets that can achieve significant scale and enhance growth through acquisitions or strategic transactions[32]. - The company will focus on acquiring businesses that are already audited by independent accountants and have appropriate corporate structures[32]. - The company anticipates structuring its initial business combination to acquire 100% of the equity interests or assets of the target business[34]. Competition and Market Conditions - The company may face intense competition from other entities with similar business objectives, which could limit its ability to acquire sizable target businesses[36]. - Risks related to geopolitical conditions and inflation may adversely affect the company's search for an initial business combination[41]. - The ongoing geopolitical instability, particularly the Russia-Ukraine conflict and the Israel-Hamas escalation, is causing significant volatility in global markets, which may adversely affect the company's search for an initial business combination[67]. - Increased inflation in the U.S. and elsewhere is leading to price volatility in publicly traded securities, complicating the company's efforts to complete a business combination[72]. - The competition for attractive business combination targets has intensified, potentially increasing costs and complicating the ability to find suitable targets[80]. Redemption and Shareholder Rights - Shareholders will have the opportunity to redeem their shares for a pro rata portion of the amount held in the Trust Account, initially set at $10.00 per share[25]. - If the initial business combination is not completed within the required timeframe, public shareholders may receive approximately $10.00 per share or less upon liquidation of the Trust Account[45]. - The ability of public shareholders to redeem shares for cash may make the financial condition unattractive to potential business combination targets[42]. - If too many public shareholders exercise their redemption rights, the company may not meet closing conditions for a business combination, making it difficult to proceed[59]. - The absence of a specified maximum redemption threshold may allow the company to complete a business combination that a majority of shareholders do not support[45]. Regulatory and Compliance Issues - The company is subject to the rules and regulations under the Exchange Act following the filing of a Registration Statement on Form 8-A[35]. - Compliance with the Sarbanes-Oxley Act may increase the time and costs associated with completing an acquisition, impacting the overall business strategy[47]. - The SEC's new rules do not provide a safe harbor for SPACs from being classified as investment companies, increasing regulatory risks[98]. - Changes in laws or regulations may adversely affect the company's ability to negotiate and complete initial business combinations[104]. - The company must ensure that investment securities do not exceed 40% of total assets to avoid being classified as an investment company[99]. Financial Risks and Liabilities - The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern[54]. - The company may face challenges in obtaining additional financing for the initial business combination or funding operations of the target business, potentially leading to restructuring or abandonment of the deal[47]. - The company may incur substantial debt to complete a business combination, which could adversely affect its leverage and financial condition, impacting shareholder value[140]. - The company has not set aside funds to cover potential indemnity obligations from Sponsor HoldCo, increasing financial risk[89]. - The Trust Account may be reduced below $10.00 per public share due to third-party claims, affecting shareholder redemption amounts[87]. Management and Personnel Risks - The management team has extensive experience in guiding companies through IPO processes and has a track record of successful mergers and acquisitions[27]. - The company currently has two officers and does not intend to have any full-time employees prior to the completion of its initial business combination[38]. - The company is dependent on a small group of key personnel, including the CEO and Co-Chairmen, which poses a risk to operations if they depart[179]. - The success of the initial business combination relies on the efforts of key personnel, some of whom may join post-combination, impacting operations and profitability[180]. - There is uncertainty regarding the retention of key personnel from the target business after the initial business combination, which could negatively affect profitability[181]. Conflicts of Interest - The company may face conflicts of interest if it engages in business combinations with entities affiliated with its co-sponsors, directors, or officers[127]. - Management and board members will own founder shares and/or private placement warrants, creating potential conflicts in target business selection[188]. - Directors and officers may have conflicts of interest due to their involvement in other business activities, potentially affecting the completion of the initial business combination[183]. - Non-managing HoldCo investors may have different interests than public shareholders due to their indirect ownership of founder shares[135]. - Key personnel may negotiate employment agreements that could create conflicts of interest in selecting target businesses for combination[182]. Cybersecurity Risks - The company lacks significant investments in data security protection, making it vulnerable to cyber incidents that could result in financial loss[213]. - Cyber incidents could lead to information theft, data corruption, operational disruption, and financial loss for the company[213]. - The company may not have sufficient resources to protect against or remediate vulnerabilities related to cyber incidents[213].

IPO and Fundraising - The company completed its Initial Public Offering (IPO) on May 13, 2024, raising gross proceeds of $287.5 million from the sale of 28,750,000 units at $10.00 per unit, including an over-allotment option [19]. - The company also sold 7,000,000 private placement warrants at $1.00 each, generating an additional $7 million in gross proceeds [20]. - Offering costs incurred in connection with the IPO were approximately $20.27 million, including deferred underwriting commissions of about $13.69 million [22]. - The company plans to utilize net proceeds from the IPO primarily for completing an initial business combination, which must have a fair market value of at least 80% of the net assets held in the Trust Account [23]. - The company has only approximately $900,000 available outside the Trust Account for working capital, which may limit its operational capabilities if the initial business combination is not completed within the required timeframe [83]. Business Combination Strategy - The company intends to target businesses with an enterprise valuation between $1.0 billion and $5.0 billion for its initial business combination [26]. - The management team aims to identify companies with strong growth trajectories and sustainable competitive advantages for potential acquisitions [28]. - The company emphasizes the importance of operational improvement and seeks candidates that may benefit from enhanced management expertise or additional capital [28]. - The company intends to focus on acquiring businesses that are operationally mature and have the necessary compliance and financial controls in place [32]. - The company aims to acquire a target that can significantly enhance shareholder value through growth and potential acquisitions [32]. Competition and Market Conditions - The company anticipates facing intense competition from other entities with similar business objectives, which may limit its ability to acquire sizable target businesses [36]. - Current global geopolitical conditions and inflation may adversely affect the company's search for a suitable business combination [42]. - The company may face challenges in completing its initial business combination due to increased competition for attractive targets and potential negative public perception of SPAC mergers [10]. - The increased number of SPACs may lead to a scarcity of attractive targets, potentially raising the costs associated with business combinations [80]. Regulatory and Compliance Issues - The company has filed a Registration Statement with the SEC and intends to maintain its reporting obligations under the Exchange Act [35]. - The company may not be able to complete its initial business combination due to regulatory reviews and approvals, including foreign investment regulations [54]. - The SEC adopted new rules for SPACs requiring additional disclosures related to business combinations, dilution, and conflicts of interest, which may increase costs and time for initial business combinations [105]. - Compliance with the Sarbanes-Oxley Act may increase the time and costs associated with completing an acquisition, particularly for a blank check company [165]. Shareholder Rights and Redemption - Shareholders will have the opportunity to redeem their shares for a pro rata portion of the amount held in the Trust Account, initially set at $10.00 per share [25]. - The ability of public shareholders to redeem shares may impact the company's financial condition and attractiveness to potential business combination targets [41]. - If too many public shareholders exercise their redemption rights, the company may not meet closing conditions for a business combination, making it difficult to proceed [59]. - If the company does not conduct redemptions in connection with its initial business combination, shareholders holding more than 15% of Class A ordinary shares may lose the ability to redeem those excess shares [78]. Financial Risks and Concerns - The independent registered public accounting firm's report expresses substantial doubt about the company's ability to continue as a going concern [54]. - The company may not be able to obtain additional financing to complete its initial business combination, which could compel it to restructure or abandon a particular business combination [47]. - The company may face difficulties in negotiating and completing an initial business combination due to changes in the market for directors and officers liability insurance [10]. - The company may incur substantial debt to complete a business combination, which could adversely affect its leverage and financial condition, impacting shareholder value [140]. Management and Personnel - The management team has extensive experience in guiding companies through IPO processes and has a track record of successful mergers and acquisitions [27]. - The company is dependent on a small group of key personnel, including the CEO and Co-Chairmen, for its operations and success, which poses a risk if any of them depart [179]. - There is uncertainty regarding the retention of key personnel from the target business after the initial business combination, which could negatively affect the post-combination business [181]. - Key personnel may negotiate employment agreements with the target business, creating potential conflicts of interest in selecting advantageous business combinations [182]. Conflicts of Interest - The company may face conflicts of interest if it engages in business combinations with entities affiliated with its co-sponsors, directors, or officers [127]. - Directors and officers may have conflicts of interest due to their involvement in other business activities, which could limit their time and focus on the company's affairs [183]. - The non-managing HoldCo investors may have different interests than other public shareholders due to their indirect ownership of founder shares [135]. Market and Trading Risks - The company's securities may be delisted from Nasdaq, which could limit trading and liquidity for investors [191]. - If securities are delisted and not listed on another exchange, it could lead to significant adverse consequences, including reduced liquidity and increased regulatory scrutiny [192]. - The potential issuance of additional Class A ordinary shares upon exercise of warrants could make the company a less attractive acquisition vehicle [161]. - The company's amended and restated memorandum and articles of association may inhibit takeovers, potentially limiting the price investors might be willing to pay for Class A ordinary shares [208]. Cybersecurity Risks - The company lacks significant investments in data security protection, making it vulnerable to cyber incidents that could result in financial loss [213]. - Cyber incidents could lead to information theft, data corruption, operational disruption, and financial loss for the company [213].

Financial Performance - The company incurred net losses of $146.9 million and $113.9 million for the years ended December 31, 2025 and 2024 respectively, with an accumulated deficit of $1,553 million as of December 31, 2025 [271]. - Cash and cash equivalents were $194.2 million as of December 31, 2025, with an additional gross proceed of $94 million (€81 million) from the exercise of warrants [275]. - The company anticipates significant increases in research and development expenses as it seeks regulatory approval for Viaskin Peanut, which may lead to substantial operating losses [274]. - The company may need to raise additional capital through public or private equity or debt financings to support ongoing research and development efforts [276]. - The company has not generated product revenue and is preparing for the potential launch of its first product, Viaskin Peanut, if approved [275]. - The company anticipates requiring additional financing to fund operations, with capital needs dependent on various factors including clinical trial costs and regulatory approvals [293]. - The company is currently not generating revenue and has historically recorded significant operating losses, with the commercialization phase of the Viaskin Peanut patch contingent upon access to additional financing [392]. Regulatory and Compliance Risks - The company is obligated to maintain effective internal controls over financial reporting, and any weaknesses identified could affect investor confidence and the value of its shares [290]. - The company faces risks related to economic downturns, inflation, and interest rate increases, which could adversely impact its financial performance [283]. - The FDA has previously issued a Complete Response Letter (CRL) regarding the Viaskin Peanut BLA, citing concerns that require modifications and additional data [306]. - The company may need to conduct additional clinical trials or face delays in obtaining regulatory approval, which could adversely affect its business prospects [304]. - The company is subject to significant legal and compliance costs as a U.S. public company, which may strain resources and divert management's attention [296]. - The company may face significant penalties for non-compliance with regulatory requirements, including potential product withdrawals and recalls [323][325]. - The company must provide data demonstrating the safety and efficacy of its product candidates to the FDA before commercialization, which is inherently uncertain and resource-intensive [315][316]. - The company is exposed to risks related to intellectual property claims and compliance with dual regulatory frameworks as both a U.S. and French public company [299]. - The company faces risks related to regulatory compliance and quality assurance from third-party manufacturers, which could lead to significant delays or sanctions [333]. Clinical Development and Trials - The company is conducting the OLE phase of the VITESSE Phase 3 study for children aged 4 to 7 and a supplemental safety study for toddlers aged 1 to 3, with positive results critical for regulatory approval [301]. - The company faces risks related to the lengthy and expensive clinical trial process, with a high likelihood of failure impacting development and commercialization efforts [305]. - Clinical trials for product candidates are expensive and time-consuming, with potential delays due to safety and efficacy demonstrations, adverse effects, and regulatory approval processes [309][310]. - More than 12 clinical trials for Viaskin Peanut and Viaskin Milk have been conducted with over 2,000 human subjects to evaluate safety and efficacy [368]. - Adverse events in clinical trials primarily involved skin and immune system conditions, with one reported case of mild to moderate anaphylaxis [368]. Market and Competitive Landscape - Future revenue will depend on market acceptance and reimbursement for Viaskin Peanut, with potential revenue prospects being affected by the prevalence of peanut allergies [271]. - The biopharmaceutical industry is highly competitive, with numerous companies having greater resources and experience, which may hinder the company's ability to discover and commercialize products successfully [351]. - The market acceptance of product candidates will depend on clinical efficacy, safety, approved labeling, and the ability to educate the medical community about the product [352]. - Government and healthcare payor cost-containment initiatives may negatively impact revenue generation if regulatory approval is obtained [357]. - The company faces potential pricing pressures from both federal and state levels in the U.S. and internationally, which may affect future product sales [365]. Intellectual Property and Legal Risks - The ability to protect proprietary rights is essential for competitive advantage, with uncertainties surrounding patent protection and potential challenges from third parties [394]. - Legal actions to enforce patent rights can be costly and may divert management resources, impacting the company's competitive position [400]. - The company may face claims from third parties regarding the ownership of inventions developed through collaborations, potentially limiting its market opportunities [413]. - The biopharmaceutical industry is characterized by extensive litigation, and any successful claims against the company could lead to substantial damages and hinder product commercialization [418]. Operational and Supply Chain Risks - The company is dependent on third parties for the supply of materials necessary for the production of Viaskin patches, which could be interrupted due to global crises or supply chain issues [328]. - The company currently relies on Sanofi S.A. as the sole manufacturer for the active pharmaceutical ingredients (API) used in Viaskin product candidates, which poses risks for timely supply [331]. - The company does not currently own manufacturing facilities and relies on third parties for production, which could complicate supply chain management and increase costs [463]. - Future tariffs and trade restrictions may increase research and development expenses and disrupt supply chains, negatively impacting the company's growth prospects [465]. Cybersecurity and Data Privacy - The company is subject to stringent data privacy and security obligations, with potential fines under the EU GDPR of up to €20 million or 4% of annual global revenue, whichever is greater [445]. - Cyberattacks and online fraud are increasing threats that could disrupt the company's operations and lead to significant financial losses [454]. - Compliance with data privacy and security obligations may lead to costly disclosures and potential government enforcement actions, impacting the company's operations and reputation [458]. Management and Personnel Risks - The loss of key personnel could adversely impact the company's ability to achieve its research and commercialization objectives [421]. - Key management or scientific personnel changes could affect company stability and performance [469].

Store Operations - The Company operated 829 retail stores and 60 franchise stores as of January 31, 2026, with a total of 889 stores across the Americas, EMEA, and APAC regions[27] - In Fiscal 2025, the Company opened 62 new store locations, remodeled 47 locations, and closed 22 stores, indicating a focus on optimizing store presence[23] Sourcing and Supply Chain - Approximately 37% of merchandise receipts in Fiscal 2025 were sourced from vendors in Vietnam, while 26% were from Cambodia, highlighting the geographic distribution of sourcing[30] - The Company utilizes an agile inventory model to optimize inventory levels and respond quickly to customer demand trends[29] Financial Performance and Strategy - The Company expects to maintain double-digit operating margins and expand net income per diluted share as part of its financial discipline strategy[22] - The Company aims to deliver consistent global growth by investing in owned-and-operated channels and expanding into new markets through franchise and licensing partnerships[22] Digital Engagement - Over 89% of the Company's digital traffic in Fiscal 2025 was generated from mobile devices, emphasizing the importance of mobile engagement[21] - The Company continues to invest in its digital infrastructure, including a new merchandising ERP system that went live in March 2026[20] Customer Engagement - The loyalty programs, myAbercrombie and Hollister House Rewards, are designed to enhance customer engagement and drive repeat business through rewards and personalized offers[34] Workforce and Culture - The Company employed approximately 43,200 associates globally as of January 31, 2026, with about 36,600 being part-time associates[44] - The Company aims to create a culture of belonging and respect, with initiatives to ensure all associates feel represented and included[47] - The Company provides competitive compensation and benefits, including cash-based and equity-based incentive awards, to attract and retain key talent[47] - The Company has a focus on community involvement, offering a paid volunteer day each year for eligible volunteer work[47] - The Board of Directors oversees human capital matters, including compensation structure and human capital management strategies[46] - The Company has policies in place to create a work environment free from abuse, harassment, or discrimination[44] - The Company believes that the attraction, retention, and management of qualified talent are integral to its success[44] Financial Management and Risks - The Company maintains its cash equivalents in financial instruments, primarily time deposits and money market funds, with original maturities of three months or less[270] - The Company redeemed all of its outstanding 8.75% Senior Secured Notes on July 15, 2024, eliminating interest rate risk[272] - The Company has exposure to foreign currency exchange rate fluctuations due to international operations, which are translated into U.S. dollars for financial reporting[273] - A&F utilizes foreign currency exchange forward contracts to mitigate risks associated with foreign currency transactions and forecasted transactions[274] - A hypothetical 10% devaluation of the U.S. dollar could decrease the fair values of derivative instruments by approximately $13.9 million[275] - The Company does not engage in currency speculation with forward contracts, focusing instead on cash flow hedges for forecasted transactions[275] - The impact of foreign currency exchange rate fluctuations is expected to increase as international operations grow relative to domestic operations[273] - The fair value of outstanding foreign currency exchange forward contracts is recorded at the end of each fiscal period[274] - The Company has established a program to partially offset foreign currency exchange rate risks, which includes gains or losses on forward contracts[274] - For a detailed discussion of material risk factors, refer to "ITEM 1A. RISK FACTORS" in the Annual Report[276] - The Company’s financial statements are affected by the translation of foreign currencies into U.S. dollars at the end of the reporting period[273] Competitive Environment - The Company operates in a highly competitive retail environment, competing on product quality, brand messaging, and immersive shopping experiences[35]

Financial Performance - The company incurred net losses of approximately $7.8 million and $12.3 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of approximately $73.2 million as of December 31, 2025[151]. - The company has never generated revenue from operations and may not do so for several months or years, if ever[151]. - The company anticipates continuing to incur substantial expenses without corresponding revenues as it attempts to launch its first commercial product[151]. - The company may require additional capital to fund operations and support commercialization activities, with existing cash potentially covering anticipated expenditures for the development of the Tome Foundational Treatment[155]. - The company is subject to substantial doubt about its ability to continue as a going concern, as indicated by its independent auditors[159]. Market and Competitive Risks - The company operates in a highly competitive skincare industry, which may adversely affect its results if it cannot compete effectively[147]. - The skincare industry is highly competitive, with significant pressure from multinational companies that have greater resources and brand recognition[171]. - Consumer spending habits are influenced by economic conditions, which could adversely affect demand for the company's products[188]. - The acceptance of new product launches may not meet expectations, impacting sales and market performance[177]. - The company may experience declines in average selling prices due to various factors, including changes in discount programs and economic conditions[189]. Regulatory and Compliance Risks - The company faces risks related to manufacturing, including the ability to secure sufficient raw materials and meet regulatory requirements for product launch[147]. - Regulatory risks associated with the shift from Rx to OTC monograph pathways could delay product launches and increase costs[167]. - The company has withdrawn the investigational new drug application for XYNGARI, focusing instead on an OTC acne kit that must comply with FDA regulations[168]. - The company expects to encounter increased regulatory and compliance requirements, which could disrupt operations and affect financial performance[212]. - Compliance with new regulations under the MoCRA, effective December 29, 2023, will require significant capital investment to ensure manufacturing practices meet the new standards[255]. Supply Chain and Operational Risks - The company relies on a single supplier for the raw material used in its sponge powder, which poses risks related to supply disruptions and environmental conditions affecting harvests[215]. - The company faces risks from third-party suppliers and distributors, which may not meet quality standards or regulatory requirements, potentially harming brand reputation[209]. - New sanctions and trade restrictions related to Russia could impact the company's ability to fulfill supply agreements, potentially leading to production interruptions and increased costs[221]. - The company faces risks related to inventory management, including potential obsolescence and the need to lower sale prices, which could negatively affect profit margins[226]. - The company may face challenges in managing third-party delivery services, which are critical for timely product distribution[222]. Brand and Marketing Challenges - Brand recognition is relatively low compared to competitors, making it essential for the company to enhance its reputation and consumer perception[180]. - Increased marketing expenditures are planned to raise brand awareness, but there is no assurance that these efforts will yield the desired returns[227]. - The company plans to rely heavily on social media for marketing, which could expose it to reputational risks and legal liabilities if negative commentary arises[277]. - The company has limited marketing capabilities and must establish or partner for sales and distribution to successfully commercialize products[290]. Intellectual Property Risks - The ability to obtain and enforce patent rights is uncertain, which may hinder the company's competitive position against third parties[304]. - The company may face challenges in protecting intellectual property rights in foreign jurisdictions, which could harm business prospects[309]. - Changes in patent laws and regulations could diminish the value of intellectual property and narrow the scope of patent protection[315]. - The company faces potential litigation risks related to patent infringement claims, which could be costly and time-consuming, adversely affecting operating results[320]. Management and Strategic Risks - Retaining key management personnel is essential for success, as their loss could adversely affect business operations and investment opportunities[207]. - The ability to manage growth effectively is critical, requiring enhancements in operational, financial, and management systems[193]. - Achieving strategic objectives may require significant investments, potentially leading to short-term cost increases and dilutive effects on earnings[191]. - The company may need to seek licenses from third parties to avoid infringement claims, which may not be available on commercially acceptable terms[323]. Legal and Litigation Risks - Regulatory enforcement actions or civil litigation could result in significant financial and reputational damage to the company[185]. - Product liability exposure is a significant risk, with potential for substantial liabilities if claims arise from product use[261]. - Potential disputes may require the company to engage in costly and time-consuming litigation or arbitration[343]. - Adverse outcomes from disputes could result in the company paying damages, royalties, or other amounts, and could restrict business operations[343].

Financial Performance - Dermata raised $15.4 million in gross proceeds during 2025 and early 2026, expected to fund operations into Q1 2027[6] - As of December 31, 2025, Dermata had $7.5 million in cash and cash equivalents, up from $3.2 million as of December 31, 2024[7] - Total operating expenses for 2025 were $7.8 million, down from $12.5 million in 2024, with a net loss of $7.6 million compared to $12.3 million in the previous year[16] - Dermata's equity increased to $6.2 million as of December 31, 2025, from $1.6 million as of December 31, 2024[14] Research and Development - Research and development expenses decreased to $2.9 million in 2025 from $8.2 million in 2024, primarily due to a $5.1 million reduction in clinical expenses[8] Marketing and Administrative Expenses - Selling, general and administrative expenses increased to $4.8 million in 2025 from $4.3 million in 2024, driven by $0.7 million in marketing expenses[9] Product Development - Dermata plans to launch its first direct-to-consumer product, the Foundational Treatment, in mid-2026[6] - The Foundational Treatment is designed to renew skin appearance with a once-weekly application and will incorporate the Bioneedle ingredient[3] - Dermata is also developing a second product, the Clearing Treatment for acne, expected to launch shortly after the Foundational Treatment[6] Clinical Trials - The company announced positive topline data from its XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, achieving significant results[6]

Clinical Trials and Research - The company plans to initiate a 60-patient clinical trial in the second half of 2026 to validate its oral insulin formulation, aiming for a cost-effective approach to regulatory submissions[26] - The ORA-D-013-1 Phase 3 trial for the oral insulin capsule did not meet its primary or secondary endpoints, leading to a strategic review and a revised Phase 3 trial submission to the FDA[90][91] - The results of the ORA-D-013-1 Phase 3 trial did not meet primary or secondary endpoints, leading to a comprehensive analysis and submission of a new protocol for a Phase 3 clinical trial to the FDA[152] - The ORA-D-013-1 trial did not meet its primary or secondary endpoints, leading to the termination of the ORA-D-013-2 Phase 3 trial[160] - Alpha Tau is conducting five concurrent FDA-approved clinical trials in the U.S. and additional trials in France, Italy, Israel, and planned studies in the UK[52] - The company reported encouraging interim data from a clinical study in Israel combining Alpha DaRT with checkpoint inhibitors for head and neck cancer patients[53] - Alpha Tau anticipates a response from Japan's Ministry of Health regarding its application for Alpha DaRT in recurrent head and neck cancer, which would be its first commercial approval outside of Israel[54] - Alpha Tau is targeting completion of patient recruitment for the ReSTART pivotal trial by Q1 2026 and expects full PMA submission by year-end 2026[58] Financial Transactions and Investments - In the 2023 Scilex Transaction, the company received a senior secured promissory note with a principal amount of $101,875,000, maturing on March 31, 2026, with an interest rate of SOFR plus 8.5%[32] - The company acquired the right to receive 4% royalties on worldwide net sales of ZTLido and related products for 10 years, in exchange for a $2,500,000 reduction in the Tranche A Note[38] - The company participated in a registered direct offering by BioXcel, acquiring shares and warrants for a total consideration of $14,000,000[46] - The company purchased 14,110,121 shares of Alpha Tau Medical Ltd. at a price of $2.612 per share, for an aggregate purchase price of approximately $36,900,000[48] - The company has the right to nominate two directors to Alpha Tau's board and will receive a non-refundable fee of $3,000,000 over three years for providing investor relations services[49] - The company has approved investments of up to $10 million in real estate assets and an additional $20 million, with investments made in various projects including the Rabi Binyamin Project and land in Mevaseret Zion, Israel[180] - The company committed to invest NIS 7,000,000 (approximately $2,185,000) in the Ruby Sapphire II Investment Fund, with NIS 1,556,493 (approximately $499,000) funded as of March 26, 2026[87] - The company has purchased 150,000 shares of Pelthos Therapeutics Inc. for $1,500,000 and currently holds 143,423 shares after selling some[57] - The company has entered into a secured promissory note with Lifeward for $3,000,000 at 15% interest, maturing on May 14, 2026[61] - Lifeward issued shares and warrants to Alpha Tau in exchange for acquiring OraTech, with revenue-sharing payments of 4% from Lifeward's ReWalk products for up to 10 years[66] - The company invested approximately $36.9 million in Alpha Tau, a clinical-stage oncology therapeutics company, with the investment's value dependent on successful clinical results and regulatory approvals[182] Market and Competitive Landscape - The diabetes market is projected to grow from approximately 589 million adults with diabetes in 2024 to 853 million by 2050, highlighting significant market potential[93] - The company faces intense competition in the diabetes treatment sector from established therapeutic options, including GLP-1 receptor agonists[122] - The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and high competition, which may hinder the company's ability to compete[130] - The biotechnology industry is characterized by rapid technological developments and high competition, which may affect the company's ability to recoup R&D expenses[168] Financial Condition and Risks - The company has incurred net losses since inception and currently has only licensing revenues with no product revenues, indicating a challenging path to profitability[146] - The company expects to incur substantial expenditures related to research and development programs, which will be conducted through its strategic evaluation process[142] - The company may require substantial additional financing to implement potential strategic alternatives and continue research and development programs[144] - The company has a history of losses and cannot assure future operating results, with no products expected to be on the market for several years[146] - The company may face significant operational and financial risks if a strategic transaction is pursued, including increased expenditures and potential litigation[138] - The company may need to delay or scale back its research and development programs if adequate financing is not secured[145] - The company is dependent on third-party suppliers for raw materials and services, which poses risks to its operations[130] - The company is dependent on third-party suppliers for oral insulin capsules and lacks long-term agreements for supply[161] - The approval process for new drugs can take several months to years, with an average review lasting 18 months[116] Corporate Governance and Compliance - The company has contracted with thirteen individuals for employment or consulting arrangements, with a focus on retaining top talent[125] - The company must maintain compliance with Nasdaq listing requirements, including a minimum bid price of $1.00 per share, to avoid delisting[191] - The company has implemented anti-takeover Rights that may discourage favorable acquisitions, potentially causing substantial dilution to unauthorized acquirers[215] - Delaware law may complicate or delay changes in control or acquisitions, even if they are in the best interests of stockholders[217] - The company prioritizes cybersecurity, with measures including firewalls, intrusion detection systems, and access controls to mitigate risks[220] - The Chief Operating and Business Officer is responsible for cybersecurity protection measures and incident response[221] - The company maintains compliance programs to address potential cyber-security breaches, which could materially affect its financial position if not managed effectively[210] External Factors and Economic Conditions - The company is subject to political, economic, and military risks due to its operations in Israel, which could negatively impact its business[199] - Recent political events have led to a downgrade of Israel's credit rating from A1 to A2 in October 2023, and further to Baa1 with a negative outlook in September 2024[204] - The company is exposed to currency exchange rate fluctuations, with significant expenses in non-dollar currencies affecting financial results, particularly with the dollar's depreciation against the NIS in 2025[178] Shareholder Considerations - Stockholders may experience significant dilution if the company raises additional funds by issuing equity securities[197] - The company anticipates needing to raise capital through equity offerings, which may adversely affect the trading price of its common stock[196] - The company has outstanding 40,446,179 shares of common stock as of March 26, 2026, which could be affected by future sales from existing stockholders[189] - The company experienced a significant decline in stock price following the announcement of the ORA-D-013-1 Phase 3 trial results in January 2023[195] - The management has significant flexibility in using the net proceeds from any securities offerings, which could impact the company's future financial health[211]

Financial Performance - Net sales increased by $1,335, or 11.8%, to $12,609 for the year ended December 31, 2025, compared to $11,274 for 2024, primarily driven by increased sales from the primary customer[206] - Gross profit margin decreased to 44.6% for the year ended December 31, 2025, down from 46.2% in 2024, mainly due to rising produce costs, particularly citrus[207] - Net income for the year ended December 31, 2025, was approximately $3.5 million, a decrease of $41 from $3.6 million in 2024[205] Operating Expenses - Total operating expenses rose by $382, or 21.3%, to $2,180 for the year ended December 31, 2025, compared to $1,798 for 2024[208] - Selling, general, and administrative expenses increased by $374, or 28.8%, to $1,671 for the year ended December 31, 2025, driven by increased administrative personnel expenses in preparation for the initial public offering[209] Cash Flow and Working Capital - Working capital increased by $512, reaching approximately $2.6 million as of December 31, 2025, compared to $2.1 million in 2024[213] - Cash flows from operating activities decreased by $824, or 20.7%, to $3,150 for the year ended December 31, 2025, compared to $3,974 for 2024[217] - Net cash used in investing activities was $246 for the year ended December 31, 2025, a decrease from $684 in 2024, reflecting reduced capital spending after a significant expansion in 2024[218] Other Income and Future Funding - Total other income decreased by $79, or 48.5%, to $84 for the year ended December 31, 2025, compared to $163 in 2024[210] - The company expects to fund long-term cash requirements, including approximately $0.7 million in lease obligations, through operating cash flows and proceeds from the initial public offering in January 2026[215] Revenue Recognition and Credit Management - The Company recognizes revenue based on ASC Topic 606, with revenue recognized at the point of product delivery and customer acceptance[224] - As of December 31, 2025 and 2024, all accounts receivable were deemed fully collectible, resulting in no allowance for doubtful accounts[226] - The Company evaluates credit losses using the CECL methodology, assessing expected credit losses over the life of financial assets[227] - Credit risk is managed through customer evaluations, with management believing that credit risk is minimal and collection of receivables is probable[228] - A significant portion of revenue is derived from a limited number of customers, with no collateral required and credit policies in place to mitigate risk[229]

Product Development and Innovation - The company launched the BolaWrap® 150 in Q1 2022, a next-generation device that is smaller, lighter, and simpler to deploy than its predecessor, the BolaWrap 100, which has been phased out [27]. - The company expanded its product portfolio with the launch of WrapTactics™, a digital training platform aimed at integrating human-factors awareness and tactical proficiency [29]. - The company is investing in the development of the next-generation BolaWrap, focusing on manufacturing process improvements and design changes to reduce production costs and enhance reliability [97]. - The company is actively pursuing strategic partnerships to enhance technology integration capabilities and extend market reach [58]. - The company has acquired rights to software assets and services to enhance its Wrap Reality Cloud platform and acquired Intrensic, which includes a Body-Worn Camera and Digital Evidence Management solution [160]. Market Trends and Projections - The global non-lethal weapons market was valued at approximately $9.9 billion in 2024 and is expected to grow to approximately $19.1 billion by 2033, representing a compound annual growth rate of 7.6% [40]. - The U.S. law enforcement training market was valued at approximately $4.0 billion in 2025 and is projected to reach approximately $5.4 billion by 2032, with a compound annual growth rate of 4.5% [42]. - The global body-worn camera market was valued at approximately $2.9 billion in 2025 and is expected to reach approximately $4.1 billion by 2030, while the digital evidence management market is estimated at approximately $9.7 billion in 2025, growing to approximately $16.1 billion by 2030, with a compound annual growth rate of 10.8% [43]. - The counter-unmanned aircraft system market is projected to grow from approximately $6.6 billion in 2025 to approximately $20.3 billion by 2030, representing a compound annual growth rate of 25.1% [44]. Financial Performance and Revenue Streams - The company generates revenue through two primary streams: product sales and technology-enabled services, with a focus on expanding technology-enabled services revenue [55]. - The company reported a net loss of approximately $10.3 million for the year ended December 31, 2025, compared to a net loss of $5.9 million for 2024, primarily due to lower non-cash income and continued operating losses [110]. - A significant portion of revenue, approximately 43%, is expected to be generated from international sales in the year ending December 31, 2026 [148]. - The company anticipates fluctuations in quarterly and annual results due to various factors, which may hinder the ability to predict future operating results [206]. Regulatory and Compliance Challenges - The company continues to work with regulatory bodies to pursue reclassification of its non-lethal products, aiming to ease transfer restrictions for private security firms [45]. - The company’s products are classified as "Any Other Weapon" by the ATF, requiring compliance with federal firearms regulations [77]. - The company must obtain export licenses for its products, and compliance with U.S. export regulations could significantly affect international sales [168]. - The regulatory framework for AI technologies is rapidly changing, which may impact the company's ability to develop and commercialize AI solutions [199]. - The EU AI Act, effective from August 2, 2024, may impose additional compliance costs and affect the company's operations and financial condition [203]. Operational and Supply Chain Considerations - The company faces potential revenue volatility due to its subscription-based revenue model, which may not align with sales efforts and customer deployments [128]. - The company relies on third-party suppliers for key components, with 71% of its supply chain sourced from domestic U.S. suppliers, making it vulnerable to price increases and supply shortages [156]. - The company does not have long-term supply agreements with suppliers, increasing the risk of supply chain disruptions [158]. - Manufacturing and supply-chain challenges may arise as the company increases production capacity for new technologies [138]. Intellectual Property and Competitive Landscape - The company holds 93 issued patents and 149 pending patent applications related to non-lethal systems and digital evidence management, with expiration dates ranging from 2032 to 2047 [95]. - The law enforcement market is highly competitive, with larger companies potentially developing superior technologies that could render the company's products obsolete [192]. - The company may face substantial costs and resource diversion from potential intellectual property litigation, which could harm its operating results [187]. - Patent rights are territorial, and the company may face challenges in protecting its intellectual property rights globally, particularly in jurisdictions with weaker enforcement laws [177]. Workforce and Organizational Growth - The company employed approximately 25 full-time employees as of December 31, 2025, reflecting a 32% increase in workforce compared to the previous year, with growth concentrated in R&D, sales, and marketing [104]. - The company is committed to strengthening its domestic manufacturing footprint, having relocated to a new facility in Norton, Virginia, in September 2025 to support future growth [68]. Risks and Uncertainties - Global economic uncertainty and geopolitical conflicts may adversely affect the company's revenues and growth rates [144]. - Negative perceptions regarding privacy rights related to the company's products could harm its reputation and financial results [131]. - The company may incur substantial warranty costs due to product defects, which could adversely affect its financial position [139]. - The company faces potential delays in sales due to budgetary and political constraints affecting government agencies, which are its primary customers [155].